From Innovation to Clinical Impact
We are translating deep science into scalable non-invasive diagnostics to address critical unmet needs in women’s health.
Explore the key diagnostic applications we are advancing: each powered by our proprietary platform and designed to meet urgent clinical needs.
Preeclampsia
Our lead program targets preeclampsia through a simple, non-invasive urine test that detects a highly specific biomarker linked to the underlying biology of the disease.
This test can be performed as early as 10 weeks into pregnancy and throughout gestation. It accurately predicts all forms of preeclampsia, enabling timely, personalized clinical decisions that improve outcomes for both mother and baby.
Oncology
Circulating tumor cells (CTCs) provide rare but highly actionable insights into solid tumors. Our proprietary CTC capture technology has been validated across multiple cancer types, including breast, lung, and pancreatic cancers.
It has been deployed in a Phase II clinical trial involving 200 patients with triple-negative breast cancer.
Prenatal Testing
Circulating fetal cells in maternal blood provide a comprehensive, non-invasive window into fetal development—including access to the entire fetal genome.
Our scalable rare-cell capture platform enables efficient isolation and analysis of multiple fetal cell types. We are developing targeted assays to translate this powerful approach into clinical practice.
